Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 29Lymphoma 11Leukemia 10Lymphoma, Non-Hodgkin 8Lymphoma, Follicular 8Leukemia, B-Cell 8Recurrence 7Lymphoma, Large B-Cell, Diffuse 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Burkitt Lymphoma 5Lymphoma, Mantle-Cell 4Waldenstrom Macroglobulinemia 3Lymphoma, B-Cell, Marginal Zone 3Neoplasms 2Hodgkin Disease 2Hematologic Neoplasms 2Thrombocytopenia 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Paraproteinemias 1Oncology Patients Receiving Chemotherapy 1Melanoma 1Lymphoma, B-Cell 1Lymphocytosis 1Lymphadenopathy 1Leukemia, Lymphoid 1Fever 1Fatigue 1Disease 1Bronchiolitis Obliterans Syndrome 1Agammaglobulinemia 1

Interventions

fludarabine 4Rituximab 4ibrutinib 3blinatumomab 3Whole-Body Irradiation 3Tacrolimus 3Peripheral Blood Stem Cell Transplantation 3Mycophenolic Acid 3Melphalan 3Lenalidomide 3Cyclophosphamide 3Busulfan 3Bendamustine Hydrochloride 3fludarabine phosphate 2Patient Reported Outcome Measures 2Mesna 2venetoclax 1sargramostim 1pirtobrutinib 1ofatumumab 1mocetinostat 1lirilumab 1copanlisib 1Thiotepa 1Sirolimus 1RFT5-SMPT-dgA immunotoxin 1Mitoxantrone 1Methotrexate 1Granulocyte-Macrophage Colony-Stimulating Factor 1Granulocyte Colony-Stimulating Factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Leukemia, Lymphoid × ofatumumab × Clear all
NCT01520922 2017-01-19

Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)

Novartis

Phase 2 Completed
99 enrolled 27 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoid, Neoplasms, Recurrence, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡